B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
about
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritisPrimary mediastinal B-cell lymphoma: treatment and therapeutic targetsDelayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitisRituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.Consensus statement on the use of rituximab in patients with rheumatoid arthritisAutologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesisModern management of non-Hodgkin lymphoma in HIV-infected patients.Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host diseaseThe late adverse events of rituximab therapy--rare but there!Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Update on the use of rituximab for intractable rheumatoid arthritis.Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropeniaDrug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q27691388-538FEDAF-C3CF-4111-A777-C2FD6050749DQ28071389-2E50C4E6-0211-4441-BB96-5FA650046FFBQ28278652-63CBCAC0-6E83-43C5-A797-AA089FDBD753Q33371939-E8A763B4-351F-4CE9-B911-F628D51A8615Q33627797-F5B01AC4-ACE1-4EF8-9D4B-AF7AAC54BABDQ34072947-E5973129-8F48-4261-BCA5-F9ECD666E1F1Q34075484-21C349B4-D281-4995-8841-18C63B783E17Q34164140-EEBA06C6-AE6B-42B8-A776-43FAA4B1ECA0Q34212528-D944955C-9627-44AC-BF18-B5968F054A00Q34707354-94136394-D156-4243-8AB6-F5F1D5B1518DQ35638676-4216905E-7702-4018-A5BD-A231062287CFQ36121171-7EEBED59-E0B3-48BB-998A-F04A8C53445FQ36516345-40CF87CE-3473-4B49-ABC5-CFD954AEEF01Q36710347-C43EFF6C-554B-4432-A056-62B2F294CD86Q37162874-8883EAF7-0628-47EC-9B0D-F6D10BD668EBQ37462485-5CD35E94-E3E2-4EEB-BF6B-B6C5F669538AQ38087506-9F24C4D4-BB5F-4613-8CCB-35EB1454C358Q38993240-EF17008A-70C6-4040-A6AA-02D36C6BAB48Q39665991-3905F6E5-350A-48C5-ADB0-8109D18742F9Q41600132-60685A53-A350-49F0-BFDE-454926955F51Q44233582-CAB63133-D14F-42CD-81FB-6FFEA3B20FDDQ45360061-6D879843-5777-4903-B056-D38EB7957E84Q51119875-43825280-032F-43CB-A9CE-171707363D46Q58041614-C6654781-37E1-47AC-9122-33D40C061900Q58805821-D416BEA3-E3F1-462F-B3ED-0EF2257F7480
P2860
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@ast
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@en
type
label
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@ast
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@en
prefLabel
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@ast
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@en
P2093
P2860
P1433
P1476
B-cell recovery following ritu ...... 1 and granulocyte homeostasis.
@en
P2093
Frances Hakim
George Wright
Giovanna Tosato
Hyun Kyung Kim
John E Janik
Kieron Dunleavy
Larry Kwak
Nicole Grant
Ronald Gress
Takayuki Nakayama
P2860
P304
P356
10.1182/BLOOD-2004-08-3198
P407
P577
2005-02-17T00:00:00Z